

Міністерство охорони здоров'я України
Буковинський державний медичний університет

БУКОВИНСЬКИЙ МЕДИЧНИЙ ВІСНИК

Український науково-практичний журнал

Заснований у лютому 1997 року

Видається 4 рази на рік

Включений до Ulrichsweb™ Global Serials Directory, наукометричних і спеціалізованих баз даних Google Scholar (США), Index Copernicus International (Польща), Scientific Indexing Services (США), Infobase Index (Індія), Ukrainian research & Academy Network (URAN), НБУ ім. Вернадського, “Джерело”

ТОМ 26, № 3 (103)

2022

Редакційна колегія:

головний редактор Т.М. Бойчук,
О.А. Андрієць, О.Б. Беліков, О.С. Годованець, І.І. Заморський,
О.І. Івашук (перший заступник головного редактора),
Т.О. Ілашук, А.Г. Іфтодій, Г.Д. Коваль, О.К. Колоскова,
В.В. Кривецький (заступник головного редактора),
В.В. Максим'юк, Н.В. Пашковська,
Д.В. Проняєв (відповідальний секретар), Л.П. Сидорчук,
С.В. Сокольник, В.К. Ташук, С.С. Ткачук,
О.І. Федів, О.В. Цигикало

Чернівці: БДМУ, 2022

Редакційна рада:
К.М. Амосова (Київ), В.В. Бойко (Харків),
А.І. Гоженко (Одеса), В.М. Запорожан (Одеса),
В.М. Коваленко (Київ), З.М. Митник (Київ),
В.І. Паньків (Київ), В.П. Черних (Харків),
Герхард Дамман (Швейцарія),
Збігнев Копанські (Польща),
Дірк Брутцерт (Бельгія),
Раду Крістіан Дабіша (Румунія)
Віктор Ботнару (Респ. Молдова)

Рекомендовано до друку та до поширення через мережу Інтернет рішенням вченої ради
Буковинського державного медичного університету
(протокол № 5 від 27.10.2022 року)

Буковинський медичний вісник
(Бук. мед. вісник) – науково-
практичний журнал, що рецензується
Bukovinian Medical Herald
(Buk. Med. Herald)
Заснований у лютому 1997 р. Видається 4
рази на рік
Founded in February, 1997 Published four
times annually
Мова видання: українська, англійська
Сфера розповсюдження загальнодержавна,
зарубіжна
Свідоцтво про державну реєстрацію: серія
КВ №15684-4156 ПР від 21.09.2009

Наказом
Міністерства освіти і науки України
від 17 березня 2020 року № 409 журнал
“Буковинський медичний вісник”
включено до категорії "Б" (медичні
спеціальності – 222) переліку наукових
фахових видань України
Адреса редакції: 58002, м. Чернівці,
пл. Театральна, 2
Тел.: (0372) 55-37-54,
52-39-63
Факс: (0372) 55-37-54
e-mail: bmh@bsmu.edu.ua
Адреса електронної версії журналу в
Internet: <http://www.bsmu.edu.ua>

THE ROLE OF QUERCETIN IN THE TREATMENT OF LIVER DISEASES: THE REVIEW BASED ON EXPERIMENTAL AND CLINICAL INVESTIGATIONS**V.P. Prisyazhnyuk, B.P. Senyuk, O.V. Glubochenko, P.V. Prisyazhnyuk, O.P. Bukach***Bukovinian State Medical University, Chernivtsi, Ukraine***Key words:** quercetin, non-alcoholic fatty liver disease, hepatitis, liver fibrosis.*Bukovinian Medical Herald. 2022. V. 26, № 3 (103). P. 97-102.***DOI:** 10.24061/2413-0737.XXVI.3.103.2022.16**E-mail:**
prisyaznyuk_v@ukr.net**Abstract.** Scientific review covers current data regarding the role of quercetin in the therapeutic corrections of various liver diseases, in particular non-alcoholic fatty liver disease, chronic hepatitis, drug-induced liver disease.**The aim of the review** was to sum up current scientific data regarding quercetin properties, its mechanism of action and possibilities of this flavonoid in the treatment of various liver diseases.**Conclusions.** Quercetin is found to possess antioxidant, anti-inflammatory, hypolipidemic, antisteatotic and antifibrotic properties. The abovementioned makes this flavonoid potentially useful in the treatment of various liver disease, in particular non-alcoholic fatty liver disease, chronic hepatitis of different etiologies, and drug induced liver disease.**РОЛЬ КВЕРЦЕТИНУ У ЛІКУВАННІ ЗАХВОРЮВАНЬ ПЕЧІНКИ: ОГЛЯД ЕКСПЕРИМЕНТАЛЬНИХ ТА КЛІНІЧНИХ ДОСЛІДЖЕНЬ****В.П. Присяжнюк, Б.П. Сенюк, О.В. Глубоченко, П.В. Присяжнюк, О.П. Букач****Ключові слова:** кверцетин, неалкогольна жирова хвороба печінки, гепатит, фіброз печінки.*Буковинський медичний вісник. 2022. Т. 26, № 3 (103). С. 97-102.***Резюме.** Науковий огляд присвячений узагальненню сучасних даних щодо ролі кверцетину в терапевтичній корекції різних захворювань печінки, з-поміж яких: неалкогольна жирова хвороба печінки, хронічний гепатит, медикаментозно-асоційовані захворювання печінки.**Мета дослідження** – узагальнити сучасні наукові дані щодо властивостей кверцетину, механізму його дії та можливостей застосування цього флавоноїду в лікуванні різних захворювань печінки.**Висновки.** Встановлено, що кверцетин має антиоксидантні, протизапальні, гіполіпідемічні, антистеатотичні та антифібротичні властивості. Вищезазначене свідчить про потенційну користь цього флавоноїду у терапії різних захворювань печінки, зокрема неалкогольної жирової хвороби печінки, хронічних гепатитів різної етіології та медикаментозно-асоційованих захворювань печінки.

Introduction. Quercetin belongs to the group of flavanols – compounds of plant origin containing the main structural elements in the form of two aromatic rings A and B, connected by a three-carbon bridge, which forms pyran or pyrone (in the presence of double bond) cycle. These compounds possess antiradical activity against superoxide, hydroxyl radicals and lipid peroxide radical, acting as donors of electrons or hydrogen atoms. Quercetin increases activity of catalase and tocopherol, reduces thiobarbituric acid reactive substances content [1, 26, 30]. Flavonoids can be presented in the form of glycosides (with attached carbohydrate molecules – glycosyl groups) and aglycones (without attached carbohydrate molecules) [4, 26]. Flavonoids are characterized by a high antioxidant activity, which is most pronounced in quercetin, stimulate protein synthesis, regulate phospholipid metabolism, and possess membrane-stabilizing properties [14].

The aim of the review was to sum up current scientific data regarding quercetin properties, its mechanism of

action and possibilities of this flavonoid in the treatment of various liver diseases.

Discussion. The effect of quercetin on metabolism of carbohydrates, cholesterol, and triacylglycerols is being actively studied [24, 50]. Oral administration of quercetin in animals with metabolic syndrome improves insulin sensitivity and tolerance to carbohydrates, decreases visceral fat tissue and oxidative stress level, increases endogenous synthesis of nitrogen monoxide, and improves blood rheological properties [2]. Quercetin prevents accumulation of visceral and liver fat, an increase of cholesterol, triacylglycerols, glucose, and pro-inflammatory adipokines in the blood in the experiment on mice kept on a high-calorie diet for twenty weeks [27]. Results indicating dose-dependent features of its properties on lipid and carbohydrate metabolism are obtained in clinical studies. In particular, in the study carried out by S. Egert et al., quercetin in daily dose of 150 mg/day is found to reduce atherogenic low density lipoproteins (LDL)

Наукові огляди

plasma concentration in overweight and obese patients with metabolic syndrome [16]. However, administration of 50 mg/day of this compound does not produce a significant effect on the content of lipids and lipoproteins in the blood [17].

Quercetin reduces lipoxygenase activity, which plays a key role in the processes of atherogenesis. The active metabolite of quercetin, quercetin-3-glucuronide, inhibits the endothelium-dependent oxidation of LDL in the endothelial cells of blood vessels, thus revealing its anti-atherosclerotic effect [25]. In humans quercetin inhibits platelet aggregation and thrombus formation [23] by reducing thromboxane B2 synthesis in particular [26]. Quercetin contributes to the improvement of coronary blood circulation by inhibiting thrombogenesis and biosynthesis of vasoconstrictors and increasing elasticity of the coronary arteries. In case of acute cardiac ischemia, it reduces hemodynamic disturbances and the area of the necrotic myocardium due to inhibition of phospholipids breakdown and decrease in the concentration of free fatty acids in the cardiomyocyte membranes, as well as reduction of lipoxygenase activity [3]. Quercetin has anti-inflammatory properties due to inhibition of 5-lipoxygenase, which contributes to decline in leukotrienes synthesis from arachidonic acid. Furthermore, this flavonoid also reduces protein kinase C and calmodulin-dependent protein kinase activity [26].

The antitumor effect of this flavonoid is associated with tumor cell growth factors inhibition, decrease in the intensity of protein phosphorylation in tumor cells, decline of the protein kinase C activity, and probably potentiation of the chemotherapeutic agent action [22]. Flavonoids, and quercetin in particular, are known to reduce the risk of cancer of the colon [28], kidney [47], and pancreas [13].

Quercetin possesses valuable pharmacological properties for the treatment of various liver diseases: non-alcoholic fatty liver disease (NAFLD), chronic hepatitis, drug induced liver diseases and liver fibrosis etc. This flavonoid can influence on the development and advance of liver diseases via different pathways providing antioxidant, anti-inflammatory and antisteatotic effects together with inhibition of cellular apoptosis [41]. Furthermore, quercetin is found to have different mechanisms of action at different stages of pathological process in the liver, including regulation of peroxisome proliferation activator receptor (PPAR), uncoupling proteins and perilipin 2-related factors via brown fat activation in liver steatosis. Meanwhile, this compound inhibits stromal extracellular matrix deposition at the stage of liver fibrosis, affecting transforming growth factor- β 1 (TGF- β 1), endoplasmic reticulum stress, and apoptosis [55].

The use of quercetin reduces activity of cytolytic and cholestatic syndromes in patients with liver diseases [11, 12]. Quercetin provides normalization of the liver functional activity, regression of peroxidation syndromes and systemic inflammation in type 2 diabetes mellitus patients with hepatosis [5]. The water-soluble form of quercetin used in the experimental studies was found to help in reduction of cholesterol, triacylglycerols, glucose, total bilirubin levels, alanineaminotransferase (ALT) and

alkaline phosphatase (AP) activities, and to decline prooxidant / antioxidant system disorders in the liver [6]. The experimental study of HepG2 cells, in which steatosis was modified and then treated with quercetin, showed a decrease in the triacylglycerols content, insulin resistance, pro-inflammatory cytokines synthesis and increase in the antioxidants concentration, indicating that quercetin can be effective in the treatment of NAFLD [45]. H.Z. Ying et al. in the experiment of alimentary modeling of steatohepatitis in gerbils found that administration of quercetin in the dose of 30 and 60 mg/kg per day reduced triacylglycerols content and the size of lipid droplets in the liver, serum transaminases activity and pro-inflammatory mediators such as tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6). Collagen levels in the liver decreased in animals treated with quercetin in the dose of 60 mg/kg [50]. M. Kobori et al. investigated that the normalizing effect of quercetin on lipid metabolism was mediated through the regulation of expression of the corresponding genes. In particular, high-calorie diet-induced increase of PPAR- γ gene expression, sterol regulatory element-binding protein-1c (SREB-1c) and first apoptosis signal genes in mice, which promote lipid accumulation, were normalized after quercetin administration. At the same time, increased proliferation of PPAR- α receptors, the transcription factor that regulates fatty acid oxidation, was observed, and its proliferation is reduced under conditions of a high-fat diet (HFD) [27].

Another study has shown that quercetin and repaired feed reduce expression of SREBP-1c mRNA in the liver elevated as a result of HFD. Quercetin in the dose of 50 mg/kg and 100 mg/kg improved liver cells' pathological profile in HFD-associated NAFLD as well. Thus, the authors have shown that quercetin possesses an inhibitory effect on SREBP-1c expression and improves liver pathology in NAFLD mice [39].

In experimental studies on mice H. Yang et al. revealed that quercetin alleviated serum transaminase levels and markedly reduced type 2 diabetes mellitus-induced histological alterations of the liver of NAFLD mice. Additionally, quercetin restored superoxide dismutase, catalase, and glutathione content in the liver. Moreover, quercetin markedly attenuated type 2 diabetes mellitus-induced production of interleukin-1 β (IL-1 β), IL-6, and TNF- α [49]. M. Gori et al. by means of a novel organs-on-chip technology investigated that quercetin seemed to restrain the progression of free fatty acid-induced hepatocellular steatosis, showing a cytoprotective effect due to its antioxidant and lipid-lowering properties [20]. Y. Zhang et al. revealed a positive effect of isorhamnetin, quercetin metabolite, in reducing excess weight and liver steatosis severity [53].

There could be several pathways demonstrating how quercetin acts in case of NAFLD. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic very low density lipoproteins assembly and lipophagy by inositol-requiring enzyme 1 α / X-box binding protein spliced signaling pathway [56]. A positive role of quercetin in HFD could be realized via down-regulation of nuclear factor- κ B (NF- κ B), the transcriptional factor that stimulates inflammation, and the up-regulation of heme

oxygenase-1 (HO-1), carnitine palmitoyltransferase 1 and nuclear factor erythroid 2-related factor 2 (NRF-2), one of the major defense systems against stress-related injury [35]. Quercetin intake correlates with an increased expression of carnitine palmitoyltransferase-1a, a regulator of fatty acid oxidation in the liver and the heart [35]. P. Liu et al. have found, that quercetin improves hepatic steatosis by enhancing frataxin-mediated phosphatase and tensin homolog-induced pyruvate kinase 1 / Parkin-dependent mitophagy, which can serve as a potential preventive mechanism for NAFLD progression [31].

Quercetin is able to reduce levels of cytochrome P450 family 2 E member 1 (CYP2E1), and thus reduces CYP2E1 mediated oxidative stress. Quercetin is found to decrease obesity-induced hepatosteatosis by increasing mitochondrial oxidative metabolism via HO-1, stimulating hepatic mitochondrial oxidative metabolism [42]. Finally, quercetin is found to increase adiponectin level, an adipokine with insulin-sensitizing and antisteatotic actions [10, 33].

Another possible pathway of favorable influence of quercetin in case of NAFLD is its regulatory effect on gut microbiota that could be altered in this case. D. Poras et al. have found that quercetin supplementation decreases insulin resistance and NAFLD activity score, by reducing intrahepatic lipid accumulation via its ability to modulate lipid metabolism gene expression, CYP2E1-dependent lipoperoxidation and related lipotoxicity. Quercetin reverts gut microbiota imbalance and related endotoxemia-mediated toll like receptor-4 (TLR-4) pathway induction, with subsequent inhibition of inflammasome response and reticulum stress pathway activation, leading to the blockage of lipid metabolism gene expression deregulation. The authors support the suitability of quercetin as a therapeutic approach for obesity-associated NAFLD via its anti-inflammatory, antioxidant and prebiotic integrative properties [36].

Clinical investigations revealed that additional quercetin prescription to the basic treatment of NAFLD patients in the dose of 40 mg three times daily caused more effective improvement of cytotoxicity and metabolic intoxication [8, 37]. In addition, γ -glutamyltransferase (GGT) activity is reduced more effectively in patients with additional quercetin intake that reflects alleviation of the endogenous intoxication. Positive effect of quercetin on lipid profile in NAFLD patients was noted as well, and lowering of the total cholesterol and triacylglycerols concentration in the blood was found [8, 37], that confirms its hypolipidemic and antiatherogenic properties [16, 25]. Decrease of TNF- α plasma level with quercetin treatment was investigated. Similar results concerning reduction of TNF- α plasma concentration under the influence of quercetin administration were found in the experimental studies performed by H.Z. Ying et al. [50]. Meanwhile, the content of interleukin-10 (IL-10) in the blood did not significantly change during the treatment. Significant decline of the proatrial natriuretic peptide (proANP) concentration in the blood after the treatment with quercetin was found [9]. The abovementioned indicates its positive cardiotropic properties, as it is established that proANP is an accurate marker of cardiovascular

insufficiency [19, 43, 51], which is also noted by other scientists [3, 21].

Except its favorable influence in case of NAFLD, quercetin was investigated in experimental and clinical studies of the treatment of chronic hepatitis of different etiologies. Quercetin ameliorated liver damage and histopathological changes, and suppressed the release of inflammatory cytokines in the experimental model of autoimmune hepatitis. This flavonoid attenuated apoptosis and autophagy in concanavalin-induced autoimmune hepatitis by inhibiting TNF-associated receptor factor 6 / c-Jun N-terminal kinase pathway [48].

S. Lee et al. investigated that quercetin and its glucoside derivatives prevented ethanol-induced hepatotoxicity by decreasing hepatic aminotransferase activities and inflammatory response in HepG2 cells. Moreover, quercetin induced detoxifying enzymes via the nuclear accumulation of the NRF2 and induction of antioxidant response element gene [29]. Quercetin could elevate the expression of NRF2 / HO-1 and ameliorate ethanol-induced acute liver injury in rats. The underlying mechanism of quercetin's benefit on the liver combines its antioxidant properties and inhibitory effect on the reactive oxygen species / nuclear factor- κ B / nucleotide-binding oligomerization-like receptor family pyrin domain containing 3 inflammasome / IL-1 β and interleukin-18 pathway via inducing HO-1. Besides, quercetin upregulated the anti-inflammatory cytokine IL-10, while it was found uncorrelated with HO-1 expression [32].

Histopathological analyses revealed that treatment with quercetin markedly decreased collagen deposition, pseudolobuli development, and hepatic stellate cells activation. NF- κ B and TGF- β synthesis decreased after treatment with quercetin, indicating that antifibrotic effect of quercetin is associated with its ability to modulate NF- κ B and TGF- β production. These results suggest that quercetin may be an effective therapeutic strategy in the treatment of patients with liver damage and fibrosis [46]. In addition to quercetin, dihydroquercetin has been investigated concerning its hepatoprotective effects in the treatment of toxic hepatitis and liver fibrosis by enhancing antioxidant enzyme activity and decreasing the pro-oxidant effect [15].

According to H. Farghali et al., quercetin alleviated D-galactosamine / lipopolysaccharide-induced acute hepatotoxicity by silent information regulator T1 (SIRT1) upregulation [18]. Also, experimental research showed that 50 mg/kg of quercetin can alleviate acrylamide-induced hepatotoxicity by reducing oxidative stress and inflammatory injury and regulating lipid metabolism [52]. Quercetin was less effective in cadmium induced hepatotoxicity as it was shown in the experiments carried out by C. Vicente-Sánchez et al. whose results demonstrated that cadmium administration induced an increased marker enzyme of liver injury activity in plasma. This effect was not inhibited by quercetin. However, the administration of quercetin alleviated cadmium-induced oxidative damage [44].

Quercetin co-administration prevented the elevation of ALT, aspartate transaminase (AST), AP and bilirubin compared with isoniazid and rifampicin treatment alone in

Наукові огляди

experiment. The authors observed that quercetin prophylaxis lessened the severity of hepatic necrosis and inflammation in the histological analysis, as compared to those who received only anti-tuberculosis drugs. Quercetin attenuated anti-tuberculosis drug-induced oxidative stress by increasing NRF2 activation and expression, enhancing endogenous antioxidant levels. Quercetin blocked inflammatory mediators of high mobility group box-1 (HMGB-1) and interferon- γ (IFN- γ), inhibiting activation of NF- κ B / TLR-4 axis [40]. Similar results of a beneficial effect of quercetin in isoniazid hepatotoxicity were obtained by Y. Zhang et al., who investigated quercetin pretreatment reduced ALT and AST levels, improved liver histopathological changes and substantially mitigated apoptosis in rats [54].

In clinical studies chronic nonviral hepatitis patients who took quercetin were characterized by more effective reduce of ALT and AST activities as compared to patients who received standard treatment [7, 38]. These results are consistent with L.M. Sheremeta data, who have found out similar properties of quercetin in the experimental modeling of hepatitis [11]. Furthermore, lactate dehydrogenase and AP activities decreased in quercetin arm as well. GGT activity was more effectively decreased in patients who received a comprehensive treatment with quercetin [7, 38]. These findings reflect intoxication and cholestatic syndromes reduction in the examined patients. Administration of quercetin revealed a positive effect on lipid profile. In particular, decrease in the total cholesterol concentration in the blood was found [9].

Patients with additional quercetin intake were characterized by a significant decrease in TNF- α content in the blood, while patients receiving standard treatment demonstrated only a tendency to reduction of this proinflammatory cytokine. No reliable changes in anti-inflammatory IL-10 level in chronic hepatitis patients of both quercetin and standard treatment arms were detected [9, 38]. According to C. Montoliu et al. investigations, proANP is not only a reliable predictor of cardiovascular risk in cardiological patients but also can serve as a marker for the risk of hemodynamic complications in patients with chronic liver disease [34]. In this respect, additional to the standard treatment quercetin prescription caused significant decrease of proANP level, lessening concomitant cardio-vascular alterations in chronic hepatitis patients.

Conclusions. Quercetin is found to possess antioxidant, anti-inflammatory, hypolipidemic, antisteatotic and antifibrotic properties. The abovementioned makes this flavonoid potentially useful in the treatment of various liver disease, in particular non-alcoholic fatty liver disease, chronic hepatitis of different etiologies, and drug induced liver disease.

Prospects for further investigations. More investigations are required to specify dose-related effects of quercetin in various liver pathologies together with determination of duration of its intake and possible age-dependent differences in dose and therapeutic scheme.

Список літератури

1. Andreieva OO, Zupanets IA, Shalamai AS. Vyvchennia

hastroprotektornoj dii kombinatsii kvvertsetynu ta pokhidnykh hliukozaaminu na modeli etanol-prednizolonovoho urazhennia shlunka u shchuriv [Study of the gastroprotective effect of the combination of quercetin and glucosamine derivatives on the model of ethanol-prednisone gastric damage in rats]. *Klinichna farmatsiia*. 2009;3:32-4. (in Ukrainian).

2. Borikov OIu. Protektyvnyi efekt kvvertsetynu shchodo rozvytku metabolichnoho syndromu, indukovanoho vysokozhyrovoiu diietoiu u ovariektomovanykh shchuriv [Protective effect of quercetin on the development of metabolic syndrome induced by a high-fat diet in ovariectomized rats]. *Problemy endokrynnoi patolohii*. 2010;4:85-93. (in Ukrainian).

3. Ilashchuk TO. Korvityn u likuvanni patsiientiv iz hostrym infarktom miokarda, uskladnenym hostroiu livoshlunochkovoju nedostatnistiu [Corvutin in the treatment of patients with acute myocardial infarction complicated by acute left ventricular failure]. *Bukovynskiy medychnyi visnyk*. 2007;11(2):48-52. (in Ukrainian).

4. Kovalevska IV. Vyznachennia fizyko-khimichnykh kharakterystyk kvvertsetynu [Determination of physical and chemical characteristics of quercetin]. *Aktualni pytannia farmatsevtichnoi i medychnoi nauky ta praktyky*. 2014;1:9-11. (in Ukrainian).

5. Mazur LP, Smachylo IV, Naumova LV, Volynets KV, Krekhovska-Lepiavko OM, Yavorska IV. Viddaleni rezultaty zastosuvannia antyoksydanta kvvertsetynu u khvorykh na tsukrovoyi diabet 2 typu z hepatozom [Long-term results of the use of the antioxidant quercetin in patients with type 2 diabetes mellitus with hepatosis]. *Zbirnyk materialiv pidsumkovoju nauk.-prakt. konf. Zdobutky klinichnoi ta eksperymentalnoi medytsyny*; 2012 Apr 17; Ternopil. Ternopil; 2012. p. 49. (in Ukrainian).

6. Posokhova KA, Zozuliak NB, Nikolaieva VV. Metabolichni porushennia pry eksperymentalnomu tsukrovomu diabete 2 typu ta pryznachenni vodorozchynnoi formy kvvertsetynu [Metabolic disorders in experimental type 2 diabetes and administration of the water-soluble form of quercetin]. *Medychna ta klinichna khimii*. 2012;3:69-72. (in Ukrainian).

7. Prisyazhnyuk VP. Efektyvnist vykorystannia kvvertsetynu u khvorykh na khronichnyi hepatyt nevirusnoho pokhodzhennia riznoho viku [The effectiveness of the use of quercetin in patients with chronic hepatitis of non-viral origin of different ages]. *Halytskyi likarskyi visnyk*. 2015;1:70-3. (in Ukrainian).

8. Prisyazhnyuk VP. Osoblyvosti vykorystannia kvvertsetynu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky riznykh vikovykh hrup [Features of the use of quercetin in patients with non-alcoholic fatty liver disease of different age groups]. *Visnyk naukovykh doslidzhen*. 2015;1:23-5. (in Ukrainian).

9. Prisyazhnyuk VP, Voloshyn OI. Klinichno-patogenetychni, vikovi, genderni, genetychni aspekty nealkoholnoi zhyrovoi khvoroby pechinky ta khronichnoho hepatytu nevirusnoho pokhodzhennia bez, a takozh z komorbidnym hipotyrozom; udoskonalennia yikh likuvannia [Clinical-pathogenetic, age, gender, genetic aspects of non-alcoholic fatty liver disease and chronic hepatitis of non-viral origin without and with comorbid hypothyroidism; improvement of their treatment]. *Lvivskiy klinichnyi visnyk*. 2018;3:8-23. (in Ukrainian).

10. Radchenko OM, Slaba OR, Bek NS. Adyponektyn ta yoho rol u vnutrishnii patolohii [Adiponectin and its role in internal pathology]. *Medychna hidrolohiia ta reabilitatsiia*. 2012;10(1):11-8. (in Ukrainian).

11. Sheremeta LM. Doslidzhennia hepatoprotektornoj dii liposomalnoho kvvertsetynu pry eksperymentalnomu hepatyti [Research on the hepatoprotective effect of liposomal quercetin in experimental hepatitis]. *Halytskyi likarskyi visnyk*. 2005;1:68-9. (in Ukrainian).

12. Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. *World J*

- Gastroenterol. 2014;20(23):7366-80. DOI: 10.3748/wjg.v20.i23.7366.
13. Bobe G, Weinstein SJ, Albanes D, Hirvonen T, Ashby J, Taylor PR, et al. Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). *Cancer Epidemiol Biomarkers Prev.* 2008;17(3):553-62. DOI: 10.1158/1055-9965.EPI-07-2523.
14. Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H, et al. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). *Nutrients.* 2017;9(2):96. DOI: 10.3390/nu9020096.
15. Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, Majano PL, Benedicto I, Rosado JA, et al. Hepatitis C virus NSSA and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. *J Hepatol.* 2009;50(5):872-82. DOI: 10.1016/j.jhep.2008.12.026.
16. Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardio-vascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. *Br J Nutr.* 2009;102(7):1065-74. DOI: 10.1017/S0007114509359127.
17. Egert S, Wolfram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. *J Nutr.* 2008;138(9):1615-21. DOI: 10.1093/jn/138.9.1615.
18. Farghali H, Kemelo MK, Canová NK. SIRT1 Modulators in Experimentally Induced Liver Injury. *Oxid Med Cell Longev.* 2019;2019:8765954. DOI: 10.1155/2019/8765954.
19. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. *World J Gastroenterol.* 2014;20(37):13306-24. DOI: 10.3748/wjg.v20.i37.13306.
20. Gori M, Giannitelli SM, Zanca A, Mozetic P, Trombetta M, Merendino N, et al. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study. *Biotechnol Bioeng.* 2021;118(1):142-52. DOI: 10.1002/bit.27557.
21. Gormaz JG, Quintremil S, Rodrigo R. Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin. *Curr Top Med Chem.* 2015;15(17):1735-42. DOI: 10.2174/1568026615666150427124357.
22. Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S. Quercetin modulates NF-kappa B and AP-1/JNK pathways to induce cell death in human hepatoma cells. *Nutr Cancer.* 2010;62(3):390-401. DOI: 10.1080/01635580903441196.
23. Hubbard GP, Wolfram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. *J Thromb Haemost.* 2004;2(12):2138-45. DOI: 10.1111/j.1538-7836.2004.01067.x.
24. Jung CH, Cho I, Ahn J, Jeon TI, Ha TY. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. *Phytother Res.* 2013;27(1):139-43. DOI: 10.1002/ptr.4687.
25. Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries. *J Biol Chem.* 2008;283(14):9424-34. DOI: 10.1074/jbc.M706571200.
26. Kelly GS. Quercetin. *Altern Med Rev.* 2011;16(2):172-94.
27. Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. *Mol Nutr Food Res.* 2011;55(4):530-40. DOI: 10.1002/mnfr.201000392.
28. Kyle JA, Sharp L, Little J, Duthie GG, McNeill G. Dietary flavonoid intake and colorectal cancer: a case-control study. *Br J Nutr.* 2010;103(3):429-36. DOI: 10.1017/S0007114509991784.
29. Lee S, Lee J, Lee H, Sung J. Relative protective activities of quercetin, quercetin-3-glucoside, and rutin in alcohol-induced liver injury. *J Food Biochem.* 2019;43(11):e13002. DOI: 10.1111/jfbc.13002.
30. Li X, Jiang X, Sun J, Zhu C, Li X, Tian L, et al. Cytoprotective effects of dietary flavonoids against cadmium-induced toxicity. *Ann NY Acad Sci.* 2017;1398(1):5-19. DOI: 10.1111/nyas.13344.
31. Liu P, Lin H, Xu Y, Zhou F, Wang J, Liu J, et al. Frataxin-mediated PINK1-Parkin-dependent mitophagy in hepatic steatosis: The protective effects of quercetin. *Mol Nutr Food Res.* 2018;62(16):e1800164. DOI: 10.1002/mnfr.201800164.
32. Liu S, Tian L, Chai G, Wen B, Wang B. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation. *Food Funct.* 2018;9(8):4184-93. DOI: 10.1039/c8fo00650d.
33. Mohan SK, Veeraraghavan VP, Jainu M. Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis. *Iran J Basic Med Sci.* 2015;18(8):832-6.
34. Montoliu C, Kosenko E, Del Olmo JA, Serra MA, Rodrigo JM, Felipe V. Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis. *Liver Int.* 2005;25(4):787-95. DOI: 10.1111/j.1478-3231.2005.01066.x.
35. Panchal SK, Poudyal H, Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. *J Nutr.* 2012;142(6):1026-32. DOI: 10.3945/jn.111.157263.
36. Porras D, Nistal E, Martínez-Flórez S, Pisonero-Vaquero S, Olcoz JL, Jover R, et al. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. *Free Radic Biol Med.* 2017;102:188-202. DOI: 10.1016/j.freeradbiomed.2016.11.037.
37. Pryszazhnyuk VP, Voloshyn OI. Effects of comprehensive treatment with quercetin administration on biochemical blood parameters and pro- and anti-inflammatory cytokines in nonalcoholic fatty liver disease patients. *Pharma Innovation.* 2017;6(12):386-9.
38. Pryszazhnyuk VP. Influence of complex treatment with quercetin inclusion on cytokine profile indicators in chronic nonviral hepatitis patients. *Journal of Education, Health and Sport.* 2017;7(10):177-185. DOI: 10.5281/zenodo.1098531.
39. Saleh Al-Maamari JN, Rahmadi M, Panggono SM, Prameswari DA, Pratiwi ED, Ardianto C, et al. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. *J Basic Clin Physiol Pharmacol.* 2021;32(4):637-44. DOI: 10.1515/jbcpp-2020-0423.
40. Sanjay S, Girish C, Toi PC, Bobby Z. Quercetin modulates NRF2 and NF-κB/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo. *Can J Physiol Pharmacol.* 2021;99(9):952-63. DOI: 10.1139/cjpp-2021-0008.
41. Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis GV, Kostomitsopoulos NG, et al. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. *Saudi J Gastroenterol.* 2021;27(6):319-30. DOI: 10.4103/sjg.sjg_249_21.
42. Surapaneni KM, Priya VV, Mallika J. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). *Eur Rev Med Pharm Sci.*

Наукові огляди

2014;18(18):2736-41.

43. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. *Liver Int.* 2012;32(6):945-50. DOI: 10.1111/j.1478-3231.2011.02753.x.

44. Vicente-Sánchez C, Egido J, Sánchez-González PD, Pérez-Barriocanal F, López-Novoa JM, Morales AI. Effect of the flavonoid quercetin on cadmium-induced hepatotoxicity. *Food Chem Toxicol.* 2008;46(6):2279-87. DOI: 10.1016/j.fct.2008.03.009.

45. Vidyashankar S, Sandeep Varma R, Patki PS. Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. *Toxicol In Vitro.* 2013;27(2):945-53. DOI: 10.1016/j.tiv.2013.01.014.

46. Wan Y, Tang MH, Chen XC, Chen LJ, Wei YQ, Wang YS. Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A. *Braz J Med Biol Res.* 2014;47(8):655-61. DOI: 10.1590/1414-431x20143704.

47. Wilson RT, Wang J, Chinchilli V, Richie JP, Virtamo J, Moore LE, et al. Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. *Am J Epidemiol.* 2009;170(6):717-29. DOI: 10.1093/aje/kwp178.

48. Wu L, Wang C, Li J, Li S, Feng J, Liu T, et al. Hepatoprotective effect of quercetin via TRAF6/JNK pathway in acute hepatitis. *Biomed Pharmacother.* 2017;96:1137-46. DOI: 10.1016/j.biopha.2017.11.109.

49. Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. *Phytother Res.* 2019;33(12):3140-52. DOI: 10.1002/ptr.6486.

50. Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. *Food Chem Toxicol.* 2013;52:53-60. DOI: 10.1016/j.fct.2012.10.030.

51. Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M, et al. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. *Medicine (Baltimore).* 2017;96(18):e6712. DOI: 10.1097/MD.00000000000006712.

52. Zhang X, Li Y, Wei X, Hou Y, Jia S, Li S, et al. Metabolomics analysis of the effects of quercetin on hepatotoxicity induced by acrylamide exposure in rats. *Free Radic Res.* 2021;55(7):831-41. DOI: 10.1080/10715762.2021.1950705.

53. Zhang Y, Gu M, Cai W, Yu L, Feng L, Zhang L, et al. Dietary component isorhamnetin is a PPAR γ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. *Sci Rep.* 2016;6:19288. DOI: 10.1038/srep19288.

54. Zhang Y, Qu X, Gao H, Zhai J, Tao L, Sun J, et al. Quercetin attenuates NLRP3 inflammasome activation and apoptosis to protect INH-induced liver injury via regulating SIRT1 pathway. *Int Immunopharmacol.* 2020;85:106634. DOI: 10.1016/j.intimp.2020.106634.

55. Zhao X, Wang J, Deng Y, Liao L, Zhou M, Peng C, et al. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism. *Phytother Res.* 2021 Sep;35(9):4727-47. DOI: 10.1002/ptr.7104.

56. Zhu X, Xiong T, Liu P, Guo X, Xiao L, Zhou F, et al. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1 α /XBP1s pathway. *Food Chem Toxicol.* 2018;114:52-60. DOI: 10.1016/j.fct.2018.02.019.

Information about the author

Prysyazhnyuk Vasyl Petrovych – Doctor of Medical Sciences, Professor of the Department of Propedeutics of Internal Diseases, Bukovinian State Medical University, Chernivtsi, Ukraine.

Senyuk Bohdana Petrivna – PhD, Associate Professor of the Department of Propedeutics of Internal Diseases, Bukovinian State Medical University, Chernivtsi, Ukraine.

Glubochenko Olena Volodymyrivna – PhD, Associate Professor of the Department of Propedeutics of Internal Diseases, Bukovinian State Medical University, Chernivtsi, Ukraine.

Prysyazhnyuk Petro Vasylovych – PhD, Associate Professor of the Department of Medical and Pharmaceutical Chemistry, Bukovinian State Medical University, Chernivtsi, Ukraine.

Bukach Olha Petrivna – PhD, Assistant of the Department of Internal Medicine, Bukovinian State Medical University, Chernivtsi, Ukraine.

Інформація про авторів

Присяжнюк Василь Петрович – д-р мед. наук, проф. кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Україна.

Сенюк Богдана Петрівна – канд. мед. наук, доцент кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Україна.

Глубоченко Олена Володимирівна – канд. мед. наук, доцент кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Україна.

Присяжнюк Петро Васильович – канд. хім. наук, доцент кафедри медичної та фармацевтичної хімії, Буковинський державний медичний університет, м. Чернівці, Україна.

Букач Ольга Петрівна – канд. мед. наук, асистент кафедри внутрішньої медицини, Буковинський державний медичний університет, м. Чернівці, Україна.

*Надійшла до редакції 28.08.22
Рецензент – проф. Ванчуляк О.Л.
© В.К. Сокол, 2022*